Biomarkers in advanced liver cancer treated with tremelimumab/durvalumab
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study is looking for people with advanced liver cancer (hepatocellular carcinoma) who have not yet had systemic treatment. Participants will receive a combination of two immunotherapy drugs: tremelimumab and durvalumab (the STRIDE regimen). The goal is to find biomarkers that can predict how well the cancer responds to this treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of hepatocellular carcinoma (a type of liver cancer).
- Your liver cancer is advanced, has spread, or cannot be surgically removed.
- You have not had prior systemic anti-cancer treatment and are eligible for a specific combination therapy called STRIDE (tremelimumab and durvalumab).
- You have at least one measurable tumor on scans (or a previously treated tumor that has clearly grown).
- You are 18 years or older and covered by French social security.
- You have no medical or psychiatric condition that would make participation unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Italian study follows patients with advanced liver cancer (hepatocellular carcinoma) who receive a combination immunotherapy treatment called STRIDE for the first time. The trial tracks how well the treatment works, how it affects quality of life, and its safety in people with moderate to severe liver disease.
This trial tests a combination of two immunotherapy drugs, tremelimumab and durvalumab, for people with advanced liver cancer (HCC) who have moderate cirrhosis (Child-Pugh B). The goal is to see if this treatment can shrink tumors or slow cancer growth.
This trial tests adding lenvatinib (a targeted therapy pill) to a combination of two immunotherapy drugs (durvalumab and tremelimumab) for people with liver cancer that cannot be removed by surgery. The goal is to see if the three-drug approach works better than the two immunotherapy drugs alone.
This Phase 2 trial tests three medicines together (durvalumab, tremelimumab, and bevacizumab) to treat non-surgical (non-resectable) liver cancer. It may help shrink tumors and slow disease progression by boosting the immune system and blocking tumor blood supply.
This trial tests a combination of two drugs, zanzalintinib and durvalumab, as a maintenance treatment for people with advanced liver cancer (hepatocellular cancer) that has not gotten worse after initial treatment with tremelimumab and durvalumab. The goal is to see if this combination can help keep the cancer from growing.
This trial compares an immune “checkpoint” medicine to a targeted cancer medicine in people with advanced liver cancer who have hepatitis B in the blood. It aims to lower hepatitis B surface antigen (HBsAg) levels and see which approach works better and is safest.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.